지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.1
- 수록면
- 45 - 50 (6page)
이용수
초록· 키워드
오류제보하기
Purpose: The prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has markedly improved since the introduction of trastuzumab. We aimed to evaluate the association between stromal tumor-infiltrating lymphocyte (sTIL) or FcrR polymorphisms and survival among patients with metastatic HER2-positive breast cancer who were treated with trastuzumab. Methods: A total of 56 women with recurrent or metastatic HER2-positive breast cancer who received the trastuzumab- taxane combination as first-line treatment were included in this retrospective analysis. The single-step multiplex allele-specific real-time polymerase chain reaction technique was employed for FcrR3A genotyping. sTILs were identified via immunohistochemical analysis of surgical (n=34, 60.7%) or biopsy specimens of metastatic lesions (n=22, 39.3%). Results: We classified patients based on the sTIL level (≤10% [n=44] or >10% [n=12]); high sTIL counts were more commonly observed in patients with hormone receptor-negative tumors than in those with hormone receptor-positive tumors (34.8% vs. 12.1%, p=0.02). There was a significant association between high sTIL levels and longer progression-free survival in comparison to low sTIL levels (median, 28.4 months vs. 16.8 months; p=0.03). With regard to the FcrR3A-158 genotype, patients were classified into the Phenylalanine/Phenylalanine group (23 patients, 41.1%), Phenylalanine/Valine group (23 patients, 41,1%), or Valine/Valine group (10 patients, 17.9%); these classifications were not associated with clinical outcomes. Conclusion: High sTIL expression may be associated with better efficacy of trastuzumab-containing therapy in patients with metastatic HER2-positive breast cancer. However, this finding warrants further evaluation in the larger population.
목차
등록된 정보가 없습니다.
참고문헌 (30)
참고문헌 신청
Konecny GE / 2004 / Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients / Clin Cancer Res 10:1706~1716
Romond EH / 2005 / Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer / N Engl J Med 353:1673~1684
Slamon DJ / 2001 / Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 / N Engl J Med 344:783~792
Vogel CL / 2002 / Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer / J Clin Oncol 20:719~726
Clynes RA / 2000 / Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets / Nat Med 6:443~446
Romond EH / 2005 / Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer / N Engl J Med 353:1673~1684
Slamon DJ / 2001 / Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 / N Engl J Med 344:783~792
Vogel CL / 2002 / Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer / J Clin Oncol 20:719~726
Clynes RA / 2000 / Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets / Nat Med 6:443~446
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
A comparative study of the clinical characteristics and outcomes of hormone receptor positive, HER2 negative breast cancer patients over 65 years old and under 65 years old patients
대한임상종양학회 학술대회지
2020 .07
-
A comparative study of the clinical characteristics of breast cancer patients less than 35 years old and older patients
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .06
-
Effect of Hormone Therapy on Long-term Outcomes of Patients with Human Epidermal Growth Factor Receptor 2-and Hormone Receptor-Positive Metastatic Breast Cancer: Real World Experience in China
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
전이성 유방암의 호르몬 치료
대한내과학회지
2017 .06
-
Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years
Cancer Research and Treatment
2016 .01
-
Phosphorylated S6 Kinase-1 as Predictive Marker of Lapatinib Efficacy in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
Journal of Breast Disease
2017 .12
-
Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea
Cancer Research and Treatment
2016 .01
-
전신치료 후 장기간 종양의 유지를 보이는 전이성 유방암 환자의 임상적 특징
Journal of Breast Disease
2017 .06
-
A Case of STIL-TAL1 -positive T-lymphoblastic Leukemia With a Minor Philadelphia-positive Clone
Annals of Laboratory Medicine
2023 .01
-
A Case of T-Lymphoblastic Leukemia with Submicroscopic 1p33 Deletion Resulting in STIL-TAL1 Fusion
Laboratory Medicine Online
2023 .04
-
Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .12
-
The Role of Primary Tumor Surgery in De Novo Metastatic Breast Cancer Patients
대한외과학회 학술대회 초록집
2016 .11
-
Effects of Less than 60 Days Delay in Surgery on Tumor Progression and Survival Outcomes in Invasive Breast Cancer Patients
Journal of Breast Disease
2016 .12
-
Oncologic Effect of Oral Fluorouracil in Hormone Receptor-Negative T1a Node-Negative Breast Cancer Patients
Journal of Breast Disease
2016 .12
-
Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study
Journal of Breast Cancer
2018 .01
-
Active Treatment Improves Overall Survival in Extremely Older Non-Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study
Cancer Research and Treatment
2021 .01
-
Clinical significance of targeted next-generation sequencing for breast cancer
대한임상종양학회 학술대회지
2021 .06
-
Factors Affecting Prognosis in Metastatic Colorectal Cancer Patients
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
고령 유방암 환자의 임상병리적 특징과 예후
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2015 .06
-
Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
Cancer Research and Treatment
2022 .10
이 논문의 저자 정보
최근 본 자료
댓글(0)
0